Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Pharma, patient groups and PBMs clash as Connecticut committee considers PBM reforms
Summary
Drug makers, patient advocates and PBM trade groups debated Senate Bill 1366. Advocates sought delinking PBM compensation from list price, spread‑pricing bans and rebate transparency; PBMs warned of higher premiums and unintended consequences.
Senate Bill 1366 drew sharply contrasting testimony as pharmaceutical companies, patient advocacy groups and pharmacy benefit managers gave competing accounts of how PBM business practices affect drug prices and patient access.
Laura Hoch, associate vice president for advocacy at the National Multiple Sclerosis Society, urged the committee to curb PBM incentives that favor higher list prices. Hoch cited Federal Trade Commission reports that, she said, show PBMs may profit from arrangements that favor certain brands and can raise patient costs at the pharmacy counter: “PBMs may prefer a higher cost brand drug because it will increase their revenue,” she said.
Pharmaceutical industry representatives told the committee the bill’s core reform — removing compensation tied to drug list prices and replacing it with flat fees…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
